Related Experiment Video
Updated: May 4, 2026

Isolation and Functional Characterization of Human Ventricular Cardiomyocytes from Fresh Surgical Samples
Published on: April 21, 2014
Keynote Lecture-Transmitral hypertrophic obstructive cardiomyopathy (HOCM) repair
Friedrich W Mohr1, Joerg Seeburger1, Martin Misfeld1
1Department of Cardiac Surgery, Heart Center, University of Leipzig, Leipzig, Germany.
Insights
Hypertrophic obstructive cardiomyopathy (HOCM) surgery aims to relieve left ventricular outflow tract obstruction and mitral valve issues. Minimally invasive techniques focusing on preserving the mitral valve offer improved long-term outcomes for HOCM patients.
Area of Science:
- Cardiology
- Cardiac Surgery
- Medical Devices
Background:
- Hypertrophic obstructive cardiomyopathy (HOCM) is a disease characterized by left/right ventricular outflow tract obstruction.
- Symptoms include dyspnea, syncope, and potentially end-stage heart failure.
- Pharmacological or transcoronary ablation of septal hypertrophy (TASH) may not alleviate symptoms, necessitating surgical intervention.
Purpose of the Study:
- To describe current operative strategies for HOCM treatment.
- To emphasize relieving left ventricular outflow tract (LVOT) obstruction.
- To address systolic anterior movement (SAM) of the anterior mitral leaflet (AML) and mitral valve (MV) regurgitation.
Main Methods:
- Review of current surgical techniques for HOCM.
- Focus on myectomy with or without mitral valve replacement as a standard approach.
- Special consideration for minimally invasive subaortic LVOT myectomy with AML resuspension.
Main Results:
- Myectomy with or without MV replacement is the gold standard for HOCM.
- Mitral valve preserving techniques may improve long-term outcomes and reduce adverse events.
- Minimally invasive approaches aim to treat both HOCM and associated MV regurgitation.
Conclusions:
- Surgical intervention is crucial for symptomatic HOCM unresponsive to other treatments.
- Mitral valve preservation is preferred over replacement to minimize long-term complications.
- Minimally invasive subaortic myectomy with AML resuspension offers a promising approach for HOCM and MV regurgitation.
Abstract:
Hypertrophic obstructive cardiomyopathy (HOCM) is a heterogenous disease causing obstruction of the left and/or right ventricular outflow tract (LVOT and/or RVOT, respectively). The main symptoms include dyspnea on exertion and syncope, and in severe cases, subsequent development of heart failure symptoms with end stage heart failure occurs. In a certain number of patients, surgical intervention is required since pharmacological and/or interventional treatment using transcoronary ablation of septal hypertrophy (TASH) does not relieve symptoms. The primary goal of any surgical technique is to relieve LVOT obstruction, avoid the occurrence and/or recurrence of systolic anterior movement (SAM) of the anterior mitral leaflet (AML) and-if present-reduce mitral valve (MV) regurgitation. Depending on the configuration of LVOT obstruction, myectomy with/without MV replacement has been the "gold standard" in surgical treatment of HOCM. However, considering the known disadvantages of artificial valves, MV preserving techniques will improve postoperative outcomes and decrease major adverse events in the long term. We describe the currently available operative strategies for treatment of HOCM. Special consideration is given to minimally invasive access with subaortic LVOT myectomy and complete resuspension of the AML to treat both HOCM and MV regurgitation.
Related Concept Videos
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Cardiomyopathy V: Interprofessional Care
Cardiomyopathy IV: Restrictive Cardiomyopathy
Cardiomyopathy VII: Pre and Post Operative Nursing Management
Cardiomyopathy II: Dilated Cardiomyopathy
Mitral Stenosis III: Medical Management

